A Randomized Phase 2A, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety and Effectiveness of Collagenase Clostridium Histolyticum in the Treatment of Dupuytren Disease Nodules : Level 1 Evidence